Genelux (GNLX) Non Operating Investment Income (2024 - 2026)
Genelux (GNLX) posted Non Operating Investment Income of -$14000.0 for Q1 2026, down 1500.0% on a QoQ basis from $1000.0 in Q4 2025, and up 60.0% year-over-year from -$8750.0 in Q1 2025.
Powered by 
Analysis
Genelux (GNLX) Non Operating Investment Income (2024 - 2026) Analysis & Trends
Genelux has reported Non Operating Investment Income for 3 years, with the latest figure at -$14000.0 in Q1 2026.
- On a quarterly basis, Non Operating Investment Income rose 60.0% year-over-year to -$14000.0 in Q1 2026; TTM through Mar 2026 was -$34000.0, a 200.0% decrease from a year earlier, with the FY2025 full-year figure at -$55000.0, down 210.0% from the prior year.
- Non Operating Investment Income was -$14000.0 for Q1 2026 at Genelux, down from $1000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $135000.0 in Q3 2024, with the low at -$60000.0 in Q4 2024.
- Average Non Operating Investment Income over 3 years is -$2111.1, with a median of -$14000.0 recorded in 2026.
- The largest YoY upside for Non Operating Investment Income was 101.67% in 2025 against a maximum downside of 333.33% in 2025.
- Over 3 years, Non Operating Investment Income stood at -$60000.0 in 2024, then soared by 101.67% to $1000.0 in 2025, then slumped by 1500.0% to -$14000.0 in 2026.
- The last three Non Operating Investment Income figures came in at -$14000.0 (Q1 2026), $1000.0 (Q4 2025), and $5000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 36.64 Mn |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - | -14,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -14,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Jun 30, 2025 | -26,000.00 |
| Mar 31, 2025 | -35,000.00 |
| Dec 31, 2024 | -60,000.00 |
| Sep 30, 2024 | 135,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Mar 31, 2024 | -19,000.00 |